First-in-class Antiviral Antibody Drug Conjugates

Safely improving patient survival rates in aggressive solid tumors and their metastases with targeted therapy against novel onco-viral targets

Thelper AS is a Norwegian biotechnology company aiming to develop innovative treatments against incurable cancers. We have identified a virally encoded biomarker that is abundantly expressed in aggressive and metastatic solid tumors, but is virtually absent in healthy tissues. Our discovery enables the development of highly precise ADCs targeting cancer cells and their immunosuppressive tumor microenvironment. By sparing healthy cells (minimizing on-target, off-tumor effects) and leveraging next generation linker technologies (minimizing nonspecific effects), Thelper’s ADC candidates will greatly reduce toxicity for patients.

Our Science

We occupy a unique space in the ADC field

High tumor specificity and the potential to alleviate tumor immunosuppression differentiate our therapeutic ADC candidates along safety and durability lines. Our innovative therapies are also agnostic to viral strain variants, allowing us to reach the full spectrum of target patients suffering from aggressive, solid cancers.

Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK